CYP2A6 and the plasma level of 5‐chloro‐2, 4‐dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5‐fluorouracil, respectively, in Japanese patients with cancer given S‐1

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cancer Science

• Publication date

  2008-05-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/j.1349-7006.2008.00773.xPMID 18380793PMCID PMC11158323
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Extended safety and efficacy data on S‐1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study

  2007cited by this paper
• Proton therapy in clinical practice: current clinical evidence.

  2007cited by this paper
• Randomized Phase III study of 5-fluorouracil alone versus combination of irinotecan and cisplatin versus S-1 alone in advanced gastric cancer (JCOG9912)

  2007cited by this paper
• Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912)

  2007cited by this paper
• Randomized phase III study of S-1 alone versus S-1 + cisplatin in the treatment for advanced gastric cancer (The SPIRITS trial) SPIRITS: S-1 plus cisplatin vs S-1 in RCT in the treatment for stomach cancer

  2007cited by this paper
• Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer

  2006cited by this paper
• Disparities in gastric cancer chemotherapy between the East and West.

  2006cited by this paper
• Cytochrome P450 and anticancer drugs.

  2006cited by this paper
• Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations

  2006cited by this paper
• Novel human CYP2A6 alleles confound gene deletion analysis

  2004cited by this paper
• Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians.

  2004cited by this paper
• Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma.

  2004cited by this paper
• Effects of polymorphism in Promoter Region of Human CYP2A6 Gene (CYP2A6*9) on Expression Level of Messenger Ribonucleic Acid and Enzymatic Activity In Vivo and In Vitro

  2003cited by this paper
• Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors.

  2003cited by this paper
• Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9).

  2003cited by this paper
• Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function

  2002cited by this paper
• Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

  2002cited by this paper
• A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur.

  2002cited by this paper
• Involvement of microsomal cytochrome P450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegafur in human liver.

  2001cited by this paper
• A novel single nucleotide polymorphism altering stability and activity of CYP2a6.

  2001cited by this paper
• Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes.

  2000cited by this paper
• Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors.

  2000cited by this paper
• Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro.

  2000cited by this paper
• Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.

  1999cited by this paper
• A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502).

  1998cited by this paper
• Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects.

  1998cited by this paper
• Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity.

  1998cited by this paper
• Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry.

  1997cited by this paper
• Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats.

  1996cited by this paper
• Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats

  1996cited by this paper
• Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats.

  1993cited by this paper
• Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity.

  1988cited by this paper
• Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts.

  1987cited by this paper
• Purification and properties of dihydrothymine dehydrogenase from rat liver.

  1981cited by this paper
• Studies on Fluorinated Pyrimidines XVI. Metabolism of 5-Fluorouracil-2-C14 and 5-Fluoro-2′-deoxyuridine-2-C14 in Cancer Patients

  1963cited by this paper

• Pharmacokinetics and bioequivalence of two formulations of the S-1 (tegafur/gimeracil/oxonate) capsule in Chinese cancer patients under fasting and fed conditions: a multicenter, randomized, open-label, single-dose, double-cycle crossover study

  2025cites this paper
• Mechanistic Insights into CYP2A6 Inactivation by Visnagin and Its Impact on Pharmacokinetic Properties of Tegafur.

  2025cites this paper
• Chronopharmacokinetic model analysis of 5-fluorouracil following S-1 administration in rats: comparison with infusion and other prodrugs for chronochemotherapy.

  2025cites this paper
• Ocular complication induced by anticancer drug S-1: association with drug concentrations in tears

  2025cites this paper
• Effect of Liver Dysfunction on S-1 Therapy Induced Adverse Effects: A Retrospective Cohort Study

  2024cites this paper
• Genotypic and phenotypic landscapes of 51 pharmacogenes derived from whole-genome sequencing in a Thai population

  2022cites this paper
• Factors affecting the efficacy and safety of docetaxel combined with platinum in the treatment of advanced non-small cell lung cancer

  2021cites this paper
• Multicentre, phase II study of gemcitabine and S‐1 in patients with advanced biliary tract cancer: TG1308 study

  2020cites this paper
• Could CTSK and COL4A2 be specific biomarkers of poor prognosis for patients with gastric cancer in Asia?-a microarray analysis based on regional population.

  2020cites this paper
• High-throughput method to analyze tegafur and 5-fluorouracil in human tears and plasma using hydrophilic interaction liquid chromatography-tandem mass spectrometry.

  2019cites this paper
• Sex differences in the safety of S‐1 plus oxaliplatin and S‐1 plus cisplatin for patients with metastatic gastric cancer

  2019cites this paper
• Pharmacokinetic study of the oral fluorouracil antitumor agent S‐1 in patients with impaired renal function

  2019cites this paper
• Polymorphisms of genes encoding drug transporters or cytochrome P450 enzymes and association with clinical response in cancer patients: a systematic review

  2019cites this paper
• A randomized phase II study of S-1 versus capecitabine as first-line chemotherapy in elderly metastatic gastric cancer patients with or without poor performance status: clinical and pharmacogenetic results

  2018cites this paper
• Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials

  2018cites this paper
• Impact of relative dose intensity on bone marrow suppression induced by S-1: retrospective observational study

  2018cites this paper
• Variation in CYP2A6 Activity and Personalized Medicine

  2017cites this paper
• Relationship between metabolic phenotypes and genotypes of CYP1A2 and CYP2A6 in the Nigerian population

  2017cites this paper
• CYP2A6 Polymorphisms Associate with Outcomes of S-1 Plus Oxaliplatin Chemotherapy in Chinese Gastric Cancer Patients

  2017cites this paper
• S-1 as an option for second-line treatment of NSCLC. Is the 'East Side Story' applicable in the West?

  2017cites this paper
• Unexpected Side Effects of a High S-1 Dose: Subanalysis of a Phase III Trial Comparing Gemcitabine, S-1 and Combinatorial Treatments for Advanced Pancreatic Cancer

  2016cites this paper
• A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival

  2016cites this paper
• Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway

  2016cites this paper
• Excision repair cross-complementary group for chemotherapy efficacy in gastric cancer

  2015cites this paper
• Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study

  2015cites this paper
• Polymorphisms of CYP1A2 and CYP2A6 activity: phenotypes and the effect of age and sex in a Nigerian population

  2015cites this paper
• Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer

  2015cites this paper
• The allele frequency of CYP2A6*4 in four ethnic groups of China.

  2015cites this paper
• Effect of CYP2A6 Genetic Polymorphism on the Metabolic Conversion of Tegafur to 5-Fluorouracil and Its Enantioselectivity

  2014cites this paper
• Dose-finding study on adjuvant chemotherapy with S-1 plus oxaliplatin for gastric cancer.

  2014cites this paper
• Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the 'real world'.

  2014cites this paper
• Single tube genotyping of CYP2A6 gene deletion based on copy number determination by quantitative real-time PCR.

  2014cites this paper
• 2-13C-Uracil 呼気テストによるS-1 感受性予測

  2014cites this paper
• Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.

  2013cites this paper
• Gastric cancer pharmacogenetics: progress or old tripe?

  2013cites this paper
• Safety, compliance, and predictive parameters for dosage modification in adjuvant S‐1 chemotherapy for gastric cancer

  2013cites this paper
• Feasibility of adjuvant chemotherapy with S-1 consisting of a 4-week administration and a two-week rest period in patients with completely resected non-small cell lung cancer.

  2013cites this paper
• Pharmacokinetic Study of S-1 in Patients in Whom Inulin Clearance Was Measured

  2012cites this paper
• CYP2A6: genetics, structure, regulation, and function

  2012cites this paper
• Lacrimal drainage obstruction in gastric cancer patients receiving S-1 chemotherapy.

  2012cites this paper
• PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6

  2012cites this paper
• PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8

  2012cites this paper
• A Phase II Study of Clinical Outcomes of 3-Week Cycles of Irinotecan and S-1 in Patients with Previously Untreated Metastatic Colorectal Cancer: Influence of the UGT1A1 and CYP2A6 Polymorphisms on Clinical Activity

  2012cites this paper
• CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients

  2011cites this paper
• A phase I study of S-1 treatment with a 3 week schedule in advanced biliary cancer patients with or without hepatic dysfunction

  2011cites this paper
• Comparison of the pharmacokinetics and pharmacodynamics of S‐1 between Caucasian and East Asian patients

  2011cites this paper
• Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity

  2011cites this paper
• The Impact of Pharmacogenetics on the Clinical Outcomes of Prodrugs

  2011cites this paper
• A Case of Diffuse Alveolar Hemorrhage Associated with Tegafur Plus Uracil and Warfarin Therapy

  2011cites this paper
• Phase I Study of Two Schedules of Oral S-1 in Combination with Fixed Doses of Oxaliplatin and Bevacizumab in Patients with Advanced Solid Tumors

  2011cites this paper
• Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes.

  2011cites this paper
• Population-based differences in treatment outcome following anticancer drug therapies.

  2010cites this paper
• Can the 2-13C-uracil breath test be used to predict the effect of the antitumor drug S-1?

  2010cites this paper
• Fixed dosing and pharmacokinetics of S-1 in Japanese cancer patients with large body surface areas.

  2009cites this paper
• ６．非小細胞肺癌患者におけるCYP2A6遺伝子多型とS-1の薬物動態

  2009cites this paper
• Polymorphism of human cytochrome P450 enzymes and its clinical impact

  2009cites this paper
• Pharmacokinetics of 5-Fluorouracil in Elderly Japanese Patients with Cancer Treated with S-1 (a Combination of Tegafur and Dihydropyrimidine Dehydrogenase Inhibitor 5-Chloro-2,4-dihydroxypyridine)

  2009influential citation
• Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer.

  2009cites this paper
• Structure, function, regulation and polymorphism of human cytochrome P450 2A6.

  2009cites this paper